naabt masthead for buprenorphine site

The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Attention: Marketing Survey Opportunity - ENDING SOON

Physicians' survey: (info on the patient survey can be found here)

COMPLETED

If you have prescribed a buprenorphine-containing product for the treatment of opioid dependence at least once in the last year, please consider taking this survey sponsored by the Buprenorphine Product Manufacturers Group (BPMG). The purpose of this survey is to assess prescribers:'

The survey can be taken online or by phone. The survey will take about 15 minutes to complete. Your responses to survey questions will be anonymous.

To thank you for completing the survey, you will receive a one-time $50 gift card. You may take the survey only once every two years. Instructions for obtaining the gift card will be provided when the survey has been completed.

If you have questions about this survey or would like to take the survey by phone, please call 855-223-3922 or send an email to: BTODREMS_PMO.SM@ppdi.com.

SURVEY COMPLETED - Thank you., please click here: https://www.btodrems.com/SitePages/Survey.aspx.

*NAABT has vetted this opportunity and can confirm it is a respectable organization.

This page was last modified on : 07/07/2014

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release